RecruitingNot ApplicableNCT06388148

Endovascular Treatment for eXtra-Large Ischemic Stroke

Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial


Sponsor

Zhongming Qiu

Enrollment

286 participants

Start Date

Jun 16, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Endovascular thrombectomy and a drug called Medical management for people with stroke, acute ischemic. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMedical management

Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.

PROCEDUREEndovascular thrombectomy

Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.


Locations(2)

The First Affiliated Hospital, Hengyang Medical School, University of South China

Hengyang, Hunan, China

Xiangtan Central Hospital

Xiangtan, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06388148


Related Trials